ORBIMED ADVISORS LLC - 16 Apr 2026 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)

Reporting relationship: 10%+ Owner
Issuer ticker: TRAW
Reported as of: 16 Apr 2026
Net transaction value: +$998,207
SEC form: 4
Accepted by SEC: 28 Apr 2026, 21:41:49 UTC
Prior SEC filing: 16 Apr 2026
Next SEC filing: 21 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Traws Pharma, Inc. (TRAW) on 28 Apr 2026.

Key facts

This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Traws Pharma, Inc. (TRAW).
4 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 28 Apr 2026, 21:41.

Change

Previous filing in this sequence was filed on 16 Apr 2026.
Current net transaction value: +$998,207.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001055951 Primary reporting owner

ORBIMED ADVISORS LLC

Relationship: 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Signature date: 28 Apr 2026

CIK 0001845804

OrbiMed Capital GP VIII LLC

Relationship: 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Capital GP VIII LLC
Signature date: 28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRAW transaction

Common Stock

Purchase

Transaction value: $998,207
Shares: +597,729
Change %: +99%
Price: $1.67
Shares after: 1,203,250
Date: 16 Apr 2026
Ownership: See Footnote
Footnotes: F3, F4

TRAW transaction

Common Stock

Purchase

Transaction value: $998,207
Shares: +597,729
Change %: +99%
Price: $1.67
Shares after: 1,203,250
Date: 16 Apr 2026
Ownership: See Footnote
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAW transaction Derivative

Series A Warrants (right to buy)

Purchase

Transaction value
Shares: +597,729
Change %
Price
Shares after: 597,729
Date: 16 Apr 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 597,729
Exercise price: $1.67
Footnotes: F1, F2, F3, F4

TRAW transaction Derivative

Series A Warrants (right to buy)

Purchase

Transaction value
Shares: +597,729
Change %
Price
Shares after: 597,729
Date: 16 Apr 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 597,729
Exercise price: $1.67
Footnotes: F1, F2, F3, F4

TRAW transaction Derivative

Series B Warrants (right to buy)

Purchase

Transaction value
Shares: +597,729
Change %
Price
Shares after: 597,729
Date: 16 Apr 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 597,729
Exercise price: $1.67
Footnotes: F1, F2, F3, F4

TRAW transaction Derivative

Series B Warrants (right to buy)

Purchase

Transaction value
Shares: +597,729
Change %
Price
Shares after: 597,729
Date: 16 Apr 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 597,729
Exercise price: $1.67
Footnotes: F1, F2, F3, F4

TRAW transaction Derivative

Series C Warrants (right to buy)

Purchase

Transaction value
Shares: +1,793,187
Change %
Price
Shares after: 1,793,187
Date: 16 Apr 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 1,793,187
Exercise price: $1.67
Footnotes: F1, F2, F3, F4

TRAW transaction Derivative

Series C Warrants (right to buy)

Purchase

Transaction value
Shares: +1,793,187
Change %
Price
Shares after: 1,793,187
Date: 16 Apr 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 1,793,187
Exercise price: $1.67
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On April 15, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Investors"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the "Closing Date") Series A warrants, Series B warrants, and Series C warrants (collectively, the "Warrants") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673.

Footnote F2

The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

Footnote F3

These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

Footnote F4

This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.